Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Guadalajara
A randomized, double-blind, placebo controlled clinical trial is carried out in 24 patients with diagnosis of diabetes mellitus type 2 according to the criteria of the American Diabetes Association. Patients are assigned to two different arms: one group receives Momordica Charantia, 2 capsules with 500 mg twice daily before breakfast and dinner for 90 days or placebo, under the same scheme of treatment.
An oral glucose tolerance test is performed before and after the intervention. Matsuda index, Stumvoll index and Insulinogenic index are calculated to assess insulin sensitivity and insulin secretion.
Other clinical and laboratory parameters that are evaluated include: Body weight, body mass index, waist circumference, blood pressure, body fat percentage, fasting plasma glucose, A1C, creatinine, lipid profile and liver transaminases.
Age
35–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of diabetes mellitus type 2 according to the criteria of the American Diabetes Association (\<5 years), without pharmacological treatment (oral antidiabetic drugs or insulin) at least for three months before entering the study
Fasting glucose: \<210 mg/dl
A1C: 7-9%
Body mass index: 25-34.9 kg/m2
Body weight without variations above or under 5% in the last three months before entering the study
Women in childbearing years must have a contraceptive method
Letter of consent and release signed by each patient
You may not be if
Pregnant or suspected pregnant women
Woman breastfeeding
Medications known to affect metabolism of glucose and insulin
Personal history of liver or renal disease
Hypertension, thyroid or cardiovascular disease decompensated
Total cholesterol \>= 240mg/dl, triglycerides \>=400mg/dl, glomerular filtration rate \<=60ml/min or liver transaminases \>=2.5 the upper normal limit